Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025

Shanghai and Hong Kong, PRC, April 24, 2025 — Antengene Corporation Limited ("**Antengene**" , SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that **it will release the latest clinical data of the CD73 small molecule inhibitor ATG-037 and the mTORC1/2 small molecule inhibitor ATG-008 in Poster Presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30th to June 3rd in Chicago, IL, the United States.**

Previously, **Antengene entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) on the Phase I/IB STAMINA-01 trial** evaluating ATG-037 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with anti-PD-1 resistant solid tumors, with encouraging preliminary results in melanoma and non-small cell lung cancer (NSCLC). Currently, the dose optimization and expansion portion of the study is enrolling in China and Australia.

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室
Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China
Tel: (86) 021 3250 1095
Fax: (86) 021 3250 1062
www.antengene.com

Details of the Poster Presentations:

ATG-037 (CD73 Small Molecule Inhibitor)

Title: A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01

Abstract: 3123

Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Date: June 2, 2025

Time: 1:30 PM - 4:30 PM (Central Time)

2:30 AM - 5:30 AM, June 3, 2025 (Beijing Time)

ATG-008 (mTORC1/2 Small Molecule Inhibitor)

Title: A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy

Abstract: 5540

Session: Gynecologic Cancer

Date: June 1, 2025

Time: 9:00 AM - 12:00 PM (Central Time)

10:00 PM, June 1, 2025 - 1:00 AM, June 2, 2025 (Beijing Time)

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室
Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China
Tel: (86) 021 3250 1095
Fax: (86) 021 3250 1062
www.antengene.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Antengene

Antengene Corporation Limited (**"Antengene"**, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of **"Treating Patients Beyond Borders"**.

Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made

in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.